Uncategorized

Evanko, currently the insurer’s COO, will assume the chief executive role after Cordani retires in July.

  En 2026, el panorama profesional ha alcanzado una paradoja de productividad. Los agentes de inteligencia artificial ahora pueden ejecutar estrategias de negocio de múltiples pasos en segundos, pero los riesgos legales y regulatorios asociados con estas acciones nunca han sido tan el …

Federal regulators are planning to suspend enrollment in Elevance’s MA plans by the end of March, in a rare and serious threat to the company’s finances.

A proposed rule would cull or revise dozens of health IT certification criteria, but providers say regulators should keep some of them to avoid shifting costs or compliance responsibilities back onto clinicians. 

This webinar explores how collaborative-initiated trials and Investigator-Initiated Trials (IITs) are complementing traditional drug development to accelerate innovation, advance precision medicine, and address clinically meaningful questions.

Poplar Therapeutics is seeking a “step change” in the treatment of food allergy and other atopic conditions, with $95 million raised to date, including a $45 million series A extension that closed Tuesday.

Unos científicos han desarrollado un novedoso material capaz de retirar del agua contaminantes muy diversos, como por ejemplo arsénico, bacterias, virus, hongos, antibióticos, herbicidas, pesticidas y colorantes. El material está basado en carbón activado modificad …

In a complete response letter published by the FDA on Monday, the agency said a resubmission for REGENXBIO’s Hunter syndrome gene therapy should provide evidence of normalized or improved biomarker levels or neurodevelopmental outcomes.

The FDA last October paused Intellia Therapeutics’ late-stage CRISPR studies after detecting life-threatening enzyme elevations in one patient, who died a few days later.

OSE Immunotherapeutics has kicked off a strategic realignment initiative that involves deprioritizing the AbbVie-partnered OSE-230 and focusing its resources on the late-stage development of its ulcerative colitis candidate lusvertikimab.